Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003

Nuclear Medicine and Biology

Volumn 35, Issue 3, 2008, Pages 343-351

  Smith Jones, Peter M ^a   Pandit Taskar, Neeta ^a   Cao, Wei ^a   O'Donoghue, Joseph ^a   Philips, Martin D ^b   Carrasquillo, Jorge ^a   Konner, Jason A ^a   Old, Lloyd J ^c   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Morphotek Inc   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

DOTA; Folate receptor alpha; In 111; In 131; Monoclonal antibody

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; FOLATE RECEPTOR; FOLATE RECEPTOR ALPHA; INDIUM 111; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MORAB 003; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; ISOTOPE LABELING; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PROTEIN TARGETING;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT, ACTIVE; CARRIER PROTEINS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PILOT PROJECTS; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS; RECEPTORS, CELL SURFACE; TISSUE DISTRIBUTION;

EID: 40749130870     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2007.12.008     Document Type: Article

References (22)

1. Rettig W.J., Cordon-Cardo C., Koulos J.P., Lewis Jr. J.L., Oettgen H.F., and Old L.J. Cell surface antigens of human trophoblast and choriocarcinoma defined by monoclonal antibodies. Int J Cancer 35 4 (1985) 469-475
2. Kelemen L.E. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?. Int J Cancer 119 2 (2006) 243-250
3. Lu Y., and Low P.S. Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects. J Control Release 91 1-2 (2003) 17-29
4. van Zanten-Przybysz I., Molthoff C., Gebbinck J.K., et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. J Cancer Res Clin Oncol 128 9 (2002) 484-492
5. Molthoff C.F., Buist M.R., Kenemans P., Pinedo H.M., and Boven E. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen. J Nucl Med 33 11 (1992) 2000-2005
6. Gadina M., Canevari S., Ripamonti M., Mariani M., and Colnaghi M.I. Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma mAb MOv18. Int J Rad Appl Instrum B 18 4 (1991) 403-408
7. Andersson H., Lindegren S., Back T., Jacobsson L., Leser G., and Horvath G. Biokinetics of the monoclonal antibodies MOv 18, OV 185 and OV 197 labelled with 125I according to the m-MeATE method or the Iodogen method in nude mice with ovarian cancer xenografts. Acta Oncol 38 3 (1999) 323-328
8. Andersson H., Elgqvist J., Horvath G., et al. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin Cancer Res 9 10 Pt 2 (2003) 3914S-3921S
9. Coliva A., Zacchetti A., Luison E., et al. 90Y labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother 54 12 (2005) 1200-1213
10. Ebel W., Routhier E.L., Foley B., et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 7 (2007) 6-13
11. Markwell M.A., and Fox C.F. Surface-specific iodination of membrane proteins of viruses and eucaryotic cells using 1,3,4,6-tetrachloro-3alpha,6alpha-diphenylglycoluril. Biochemistry 17 22 (1978) 4807-4817
12. Smith-Jones P.M., Vallabahajosula S., Goldsmith S.J., et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 60 18 (2000) 5237-5243
13. Lindmo T., and Bunn Jr. P.A. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Methods Enzymol 121 (1986) 678-691
14. Roselli M., Schlom J., Gansow O.A., et al. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med 30 5 (1989) 672-682
15. Meares C.F., Moi M.K., Diril H., et al. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer Suppl 10 (1990) 21-26
16. Moi M.K., DeNardo S.J., and Meares C.F. Stable bifunctional chelates of metals used in radiotherapy. Cancer Res 50 3 Suppl (1990) 789s-793s
17. Camera L., Kinuya S., Garmestani K., et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med 35 5 (1994) 882-889
18. Lewis M.R., Raubitschek A., and Shively J.E. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjug Chem 5 6 (1994) 565-576
19. Stein R., Chen S., Haim S., and Goldenberg D.M. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft. Cancer 80 12 Suppl (1997) 2636-2641
20. Lee R.J., and Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 269 5 (1994) 3198-3204
21. Miotti S., Facheris P., Tomassetti A., et al. Growth of ovarian-carcinoma cell lines at physiological folate concentration: effect on folate-binding protein expression in vitro and in vivo. Int J Cancer 63 3 (1995) 395-401
22. Paulos C.M., Reddy J.A., Leamon C.P., Turk M.J., and Low P.S. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol 66 6 (2004) 1406-1414